[非胰岛素治疗的2型糖尿病的药理管理:HAS指南的实际实施]
1Nantes Université, CHU de Nantes, CNRS, Inserm, Institut du thorax, Nantes, France.
La Revue du praticien
|January 23, 2026
概括
法国针对2型糖尿病的新指导方针优先考虑心血管和脏健康. 他们建议在需要二次心血管预防的患者早期使用SGLT2抑制剂或GLP-1受体激动剂.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 2型糖尿病的管理需要更新的治疗策略.
- 法国卫生当局于2024年5月修订了2型糖尿病指南.
- 目前的指导方针强调改变生活方式,并将甲福明作为一线治疗.
研究的目的:
- 概述法国更新的2型糖尿病指南的实际实施.
- 突出治疗优先级向心血管和脏状况的转变.
- 定义SGLT2抑制剂和GLP-1受体激动剂在糖尿病管理中的作用.
主要方法:
- 法国卫生当局2024年5月发布的指导方针的审查和综合.
- 基于患者个人资料的治疗定位分析.
- 专注于二次心血管预防,慢性病和心力衰竭的建议.
主要成果:
- 改变生活方式和甲福明仍然是最初的治疗方法.
- 在治疗开始时,应优先考虑心血管和脏状况,而不是血糖控制.
- 建议使用SGLT2抑制剂或GLP-1受体激动剂作为二次心血管预防的早期措施.
- 对于慢性病或心力衰竭,SGLT2抑制剂是首选的,其次是GLP-1受体激活剂.
结论:
- 更新的指南代表了2型糖尿病管理的范式转变.
- 对高风险患者来说,SGLT2抑制剂和GLP-1受体激动剂的早期整合至关重要.
- 治疗决策应以全面的患者评估为指导,包括心血管和脏健康.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.4K
Insulin Formulations: Types and Delivery
676
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
676
Diabetes: Management and Pharmacotherapy
883
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
883
Cardiopulmonary Resuscitation IV: Pharmacological Management
718
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
718
Diabetes Mellitus: Overview and Type I Subtype
5.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.0K
Inflammatory Bowel Disease IV: Pharmacological Management
553
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
553


